ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
76 hedge funds and large institutions have $631M invested in Adaptimmune Therapeutics in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
7% more funds holding
Funds holding: 71 → 76 (+5)
0.73% more ownership
Funds ownership: 9.26% → 9.99% (+0.73%)
27% less call options, than puts
Call options by funds: $721K | Put options by funds: $983K
Holders
76
Holding in Top 10
4
Calls
$721K
Puts
$983K
Top Buyers
| 1 | +$18.7M | |
| 2 | +$14.7M | |
| 3 | +$10.2M | |
| 4 |
Millennium Management
New York
|
+$7.55M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$7.24M |
Top Sellers
| 1 | -$11.8M | |
| 2 | -$9.03M | |
| 3 | -$4.68M | |
| 4 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$2.61M |
| 5 |
Axa
Paris,
France
|
-$1.98M |